Neisseria meningitidis antigens and compositions

Patent metadata

Field	Value
Publication number	US-9249198-B2
Application number	US-201414450082-A
Country	US
Kind code	B2
Filing date	Aug 1, 2014
Priority date	May 1, 1998
Publication date	Feb 2, 2016
Grant date	Feb 2, 2016

Abstract

The invention provides proteins from Neisseria meningitidis , including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

First claim

We claim:

1. A method of preparing an immunogenic composition comprising:
(a) expressing in E. coli a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO: 2534, wherein the fragment comprises 18 or more consecutive amino acids from the amino acid sequence, wherein the polypeptide is immunogenic;
(b) purifying the polypeptide;
(c) preparing the immunogenic composition by combining the purified polypeptide with an aluminum salt adjuvant.

2. The method of claim 1 , wherein the fragment comprises 20 or more consecutive amino acids from the amino acid sequence of SEQ ID NO: 2534.

3. The method of claim 1 , wherein the immunogenic composition further comprises a pharmaceutically acceptable carrier.

4. The method of claim 1 , wherein the aluminum salt is aluminum phosphate.

5. The method of claim 3 , wherein the aluminum salt is aluminum phosphate.

6. The method of claim 1 , wherein the immunogenic composition further comprises a pH buffering agent.

7. The method of claim 5 , wherein the immunogenic composition further comprises a pH buffering agent.

8. A method of preparing an immunogenic composition comprising combining a purified polypeptide with an aluminum salt adjuvant, wherein the purified polypeptide was expressed in, and purified from, E. coli ; comprises a fragment of the amino acid sequence of SEQ ID NO: 2534, wherein the fragment comprises 18 or more consecutive amino acids from the amino acid sequence; and is immunogenic.

9. The method of claim 8 , wherein the fragment comprises 20 or more consecutive amino acids from the amino acid sequence of SEQ ID NO: 2534.

10. The method of claim 8 , wherein the immunogenic composition further comprises a pharmaceutically acceptable carrier.

11. The method of claim 8 , wherein the aluminum salt is aluminum phosphate.

12. The method of claim 10 , wherein the aluminum salt is aluminum phosphate.

13. The method of claim 8 , wherein the immunogenic composition further comprises a pH buffering agent.

14. The method of claim 12 , wherein the immunogenic composition further comprises a pH buffering agent.

Assignees

• Glaxosmithkline Biolog Sa

Inventors

• Fraser Claire
• Galeotti Cesira
• Grandi Guido
• Hickey Erin
• Masignani Vega
• Mora Marirosa
• Petersen Jeremy
• Pizza Mariagrazia
• Rappuoli Rino
• Ratti Giulio
• Scarlato Vincenzo
• Scarselli Maria
• Tettelin Herve
• Venter J Craig

Classifications

• Y10S530/806

  Antigenic peptides or proteins · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• Y10S530/825

  Bacteria · CPC title

• A61P31/04

  Antibacterial agents · CPC title